10-Q/A: Avid Bioservices Restates Q2 Financials Due to Debt Classification Error

Avid Bioservices has amended its Q2 financials to correct the classification of its 2026 convertible notes as a current liability and to adjust for understated interest expenses.

Summary

• Avid Bioservices has filed an amended 10-Q/A report to restate its unaudited condensed consolidated financial statements for the quarter ended October 31, 2023.
• The restatement was triggered by an acceleration notice from a holder of its 1.250% Exchangeable Senior Notes due 2026, which led to the reclassification of these notes as a current liability.
• This reclassification resulted in an understatement of current liabilities and an understatement of interest expense for the three and six months ended October 31, 2023.
• The company also identified a material weakness in its internal control over financial reporting related to the review of information about the 2026 notes.
• The amended report includes updated financial statements, management's discussion and analysis, and controls and procedures.
• The company's revenue for the quarter was $25.4 million, down from $34.8 million in the same period last year, and the company reported a net loss of $9.5 million.
• For the six months ended October 31, 2023, revenue was $63.1 million, down from $71.4 million in the prior year, and the net loss was $11.6 million.

Sentiment

Score: 3

Explanation: The document reveals significant issues including a restatement of financials, a material weakness in internal controls, and a decrease in revenue and profitability. While the company has taken steps to address these issues, the overall tone is negative from an investment perspective.

Positives

• The company's backlog increased to approximately $199 million, indicating strong future demand.
• The completion of the CGMP manufacturing suites in the cell and gene therapy facility expands the company's capacity and capabilities.
• The company has taken steps to remediate the identified material weakness in internal controls.

Negatives

• The company's Q2 2023 revenue decreased by 27% compared to the same period last year.
• The company reported a net loss of $9.5 million for the quarter and $11.6 million for the six months ended October 31, 2023.
• The restatement of financials indicates a material weakness in internal control over financial reporting.
• The reclassification of the 2026 notes as a current liability resulted in negative working capital.

Risks

• The company's disclosure controls and procedures were not effective at the reasonable assurance level.
• The company's internal control over financial reporting was not effective as of the end of each of the periods covered by the restatement.
• The company's ability to raise additional capital in the equity and debt markets is dependent on several factors including, but not limited to, the market demand for its common stock.
• The company's backlog is subject to risks such as customer cancellations, program delays, and supply chain issues.

Future Outlook

The company believes that its existing cash and cash equivalents on hand and anticipated cash flows from operating activities will be sufficient to fund its operations for at least the next 12 months. The company may draw on its revolving credit facility or obtain additional debt or equity financing if needed.

Management Comments

• Management has concluded that the company's disclosure controls and procedures were not effective at the reasonable assurance level.
• Management has identified a material weakness in the operation of internal control over financial reporting with respect to the review of information related to the 2026 Notes.
• Management has designed the necessary controls to remediate the material weakness.

Industry Context

The company operates in the contract development and manufacturing organization (CDMO) sector, which is experiencing growth due to the increasing demand for outsourced services from biotechnology and biopharmaceutical companies. The company's expansion into cell and gene therapy manufacturing aligns with the growing market for these therapies.

Comparison to Industry Standards

• The restatement of financials due to a debt classification error is not typical for well-established CDMO companies, suggesting a weakness in Avid's internal controls compared to industry leaders like Lonza or Catalent.
• The decrease in revenue and gross profit margins in the current period is concerning, as many CDMOs are experiencing strong growth due to increased demand. This suggests Avid may be facing challenges in operational efficiency or customer retention compared to peers.
• The increase in backlog is a positive sign, but the company needs to demonstrate its ability to convert this backlog into revenue and profit, which is a key metric for CDMOs like Samsung Biologics or WuXi Biologics.
• The completion of the cell and gene therapy facility is a positive development, but the company needs to demonstrate its ability to secure contracts and generate revenue from this new facility, which is a key differentiator in the competitive CDMO landscape.

Stakeholder Impact

• Shareholders will be impacted by the restatement of financials and the identified material weakness in internal controls.
• Employees may be impacted by the company's efforts to remediate the internal control issues.
• Customers may be impacted by the company's efforts to improve its operational efficiency and financial performance.
• Creditors may be impacted by the company's debt restructuring and its ability to meet its financial obligations.

Next Steps

• The company will continue to monitor and remediate the identified material weakness in internal controls.
• The company will focus on converting its backlog into revenue and improving its gross profit margins.
• The company will continue to monitor the performance of its new cell and gene therapy facility.

Key Dates

Keywords

CDMO, contract manufacturing, biologics, restatement, convertible notes, debt, financial statements, internal control, material weakness, revenue, net loss